Fecal microbiota transplantation: past, present and future
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) re-establishes a balanced intestinal flora with resultant cure of recurrent Clostridium difficile infection (RCDI). FMT has also been used to treat other gastrointestinal (GI) diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders. The purpose of this review is to discuss the intestinal microbiota and FMT treatment of GI and non-GI diseases. RECENT FINDINGS: It is known that an imbalanced intestinal microbiota predisposes to CDI, IBD and IBS. The complex role of intestinal microbiota to maintain health, however, is a newer concept that is being increasingly studied. The microbiome plays an important role in cellular immunity and energy metabolism and has been implicated in the pathogenesis of non-GI autoimmune diseases, chronic fatigue syndrome, obesity and even some neuropsychiatric disorders. SUMMARY: FMT is a highly effective cure for RCDI, but increased knowledge of the intestinal microbiota in health maintenance, as well as controlled trials of FMT in a wide range of disorders are needed before FMT can be accepted and applied clinically.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several case reports and animal models have also revealed the probable therapeutic effects of FMT in patients with severe multiple sclerosis, 41 autism, 42 multidrug-resistant organisms (MDRO) infections, 43 and multiple organ dysfunction in critical patients.44”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [42]
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 2×
“Furthermore, the obese (ob/ob) phenotype has been shown to be transmissible and is adopted in germ- free mice, infused with intestinal microbiota from conventionally raised, genetically obese mice [58].”
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 1×
“conventionally raised mice are introduced into germ-free mice [59].”
Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Self-citationGough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
(1958) · PubMed · Cited by 978
Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031
McDonald, L. C., Owings, M., & Jernigan, D. B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1203.051064 · Cited by 788
Research works printed but not linked: 12
- Borody, 1989, ust, 150, 604
- Anathaswamy, 2011, New Scientist, 2796, 8
- Eiseman, 1958, Surgery, 44, 854
- Persky, 2000, Am J Gastroenterol, 95, 3283
- Cohen, 2010, Infect Control and Hosp Epidemiol, 31, 431, 10.1086/651706 · DOI · Paper page
- Huebner, 2006, Gastroenterol Hepatol, 2, 203
- Lund-Tonnesen, 1998, Tidsskr Nor Laegeforen, 118, 1027
- Silverman, 2010, Clin Gastroenterol Hepatol, 8, 471, 10.1016/j.cgh.2010.01.007 · DOI · Paper page
- Andrews, 1995, Gastroenterology, 108, A563
- Borody, 2011, Am J Gastroenterol, 106, S352
- Borody, 2011, Am J Gastroenterol, 106, S352
- Borody, 2011, Am J Gastroenterol, 106, S352
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
“difficile, where a single dose generally leads to recovery within a few days [60].”
BackgroundCurrent Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122
“difficile infection (CDI), with a cure rate exceeding 90% to 95% worldwide.(95) Patients with CDI usually will remain on antimicrobials until 2 to 3 days before FMT.”
BackgroundAntimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence
Christaki, E., Marcou, M., & Tofarides, A. (2020) · Journal of Molecular Evolution · doi:10.1007/s00239-019-09914-3 · Cited by 780
Luczynski, P., McVey Neufeld, K.-A., Oriach, C. S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw020 · Cited by 632
“…inoculated from animal models of disease (Turnbaugh et al., 2006, 2009b; Bercik et al., 2011a; Borody and Khoruts, 2012; Cryan and Dinan, 2012; Aroniadis and Brandt, 2013; Ridaura et al., 2013; Suez et al., 2014; Thaiss et al., 2014; Leone et al., 2015), thus enabling the study of the…”
BackgroundMicrobial endocrinology: the interplay between the microbiota and the endocrine system
Neuman, H., Debelius, J. W., Knight, R., & Koren, O. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuu010 · Cited by 613
“The arrows refer to the hormone levels in GF compared to conventionally raised rodents. treated for constipation (Aroniadis and Brandt 2013).”
BackgroundPetra, A. I., Panagiotidou, S., Hatziagelaki, E., Stewart, J. M., Conti, P., & Theoharides, T. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.002 · Cited by 592
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Understanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561
Gérard, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2061-5 · Cited by 508
“Transplantation of stool for the treatment of GI disease was first reported in the fourth century in China by Ge Hong, who described the use of human fecal suspension by mouth for patients who had food poisoning or severe diarrhea [166].”
BackgroundAn update on the use and investigation of probiotics in health and disease
Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., Sherman, P. M., & Mayer, E. A. (2013) · Gut · doi:10.1136/gutjnl-2012-302504 · Cited by 503
The Gut Microbiota and Autism Spectrum Disorders
Li, Q., Han, Y., Dy, A. B. C., & Hagerman, R. J. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00120 · Cited by 462
“(Aroniadis and Brandt, 2013; Rossen et al., 2015).”
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445
The microbiome: stress, health and disease
Moloney, R. D., Desbonnet, L., Clarke, G., Dinan, T. G., & Cryan, J. F. (2014) · Mammalian Genome · doi:10.1007/s00335-013-9488-5 · Cited by 430
“…behaviours also highlights the potential benefits of faecal transplant therapy in disorders of microbiota–brain–gut axis dysregulation and the vast opportunities this method presents for further examination of the role played by microbiota in behaviour and CNS function (Aroniadis and Brandt 2013).”
MethodSmillie, C. S., Sauk, J., Gevers, D., Friedman, J., Sung, J., Youngster, I., Hohmann, E. L., Staley, C., Khoruts, A., Sadowsky, M. J., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.003 · Cited by 411
“FMT is thought to break this cycle by restoring the protective gut microbiota that inhibit the growth of C. difficile and prevent recurrence of the infection (Aroniadis and Brandt, 2013).”
BackgroundGut microbiota in autism and mood disorders
Mangiola, F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.361 · Cited by 413
The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder
Srikantha, P., & Mohajeri, M. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092115 · Cited by 400
“A healthy individual donates a stool sample [79], which is normally used freshly within eight hours or within eight weeks when directly frozen after donation [129].”
BackgroundLiévin-Le Moal, V., & Servin, A. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00080-13 · Cited by 354
“Indeed, fecal bacteriotherapy, also called fecal microbiota transplantation, has recently been successfully used as a therapy to correct the dysbiosis that characterizes chronic Clostridium difficile infection (27).”
BackgroundGut microbiome and its role in obesity and insulin resistance
Lee, C. J., Sears, C. L., & Maruthur, N. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14107 · Cited by 350
Rebuilding the Gut Microbiota Ecosystem
Gagliardi, A., Totino, V., Cacciotti, F., Iebba, V., Neroni, B., Bonfiglio, G., Trancassini, M., Passariello, C., Pantanella, F., & Schippa, S. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081679 · Cited by 340
Inflammatory Bowel Disease as a Model for Translating the Microbiome
Huttenhower, C., Kostic, A. D., & Xavier, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.013 · Cited by 332
“Clostridium difficile infection (Borody and Khoruts, 2012) highlight the great potential of microbial modulation under such circumstances, but early results for this broad-brush approach in IBD have been mixed (Aroniadis and Brandt, 2013; Sha et al., 2014; Smits et al., 2013).”
BackgroundMicrobiota regulation of the mammalian gut-brain axis
Burokas, A., Moloney, R. D., Dinan, T. G., & Cryan, J. F. (2015) · Advances in applied microbiology · doi:10.1016/bs.aambs.2015.02.001 · Cited by 300
Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats
Petriz, B. A., Castro, A. P., Almeida, J. A., Gomes, C. P., Fernandes, G. R., Kruger, R. H., Pereira, R. W., & Franco, O. L. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-511 · Cited by 293
“It has been proposed that dysbiosis and pathologies associated with unbalanced gut microbiota may be prevented or treated with prebiotics, probiotics and fecal microbiota transplantation [19,20].”
BackgroundManipulating the gut microbiota to maintain health and treat disease
Scott, K. P., Antoine, J.-M., Midtvedt, T., & van Hemert, S. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.25877 · Cited by 281
Finding alternatives to antibiotics
Allen, H. K., Trachsel, J., Looft, T., & Casey, T. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12468 · Cited by 269
Universality of human microbial dynamics
Bashan, A., Gibson, T. E., Friedman, J., Carey, V. J., Weiss, S. T., Hohmann, E. L., & Liu, Y.-Y. (2016) · Nature · doi:10.1038/nature18301 · Cited by 270
Gut-Brain Psychology: Rethinking Psychology From the Microbiota–Gut–Brain Axis
Liang, S., Wu, X., & Jin, F. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00033 · Cited by 263
“There are mainly seven recognized microbiota interventions: the GF technique, pathogen infection, antibiotics, FMT, probiotics, prebiotics, and diet (Cryan and Dinan, 2012; Aroniadis and Brandt, 2013; Cammarota et al., 2014; Liu et al., 2015); all of the methods have shown great potential in regulating mind and behavi…”
BackgroundPotential Role of the Gut Microbiome In Colorectal Cancer Progression
Kim, J., & Lee, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.807648 · Cited by 259
“Fecal microbiota transplantation (FMT) is an emerging biotherapeutic method for altering the microbiota by transplanting stool information from healthy donors to patients (110).”
MethodMartens, E. C., Kelly, A. G., Tauzin, A. S., & Brumer, H. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.06.022 · Cited by 235
“The interactions between our symbiotic gut microorganisms and dietary polysaccharides play important roles in several aspects of health [52,53,94].”
An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report
Olendzki, B. C., Silverstein, T. D., Persuitte, G. M., Ma, Y., Baldwin, K. R., & Cave, D. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-5 · Cited by 235
Fecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231
Gut microbiota: Implications in Parkinson's disease
Parashar, A., & Udayabanu, M. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.002 · Cited by 230
“Several case reports suggest the beneficial role of FMT in treating constipation in addition to marked improvement in non-GI symptoms in patients with neurological disorders [74] .”
Microbiome disturbances and autism spectrum disorders
Rosenfeld, C. S. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063826 · Cited by 229
“(Anathaswamy, 2011), and there is an anecdotal report of beneficial effects in two ASD children receiving FMT (Aroniadis and Brandt, 2013).”
BackgroundMethodInfluentialUpdate of probiotics in human world: A nonstop source of benefactions till the end of time
Zommiti, M., Feuilloley, M. G. J., & Connil, N. (2020) · Microorganisms · doi:10.3390/microorganisms8121907 · Cited by 225
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis
Olejniczak-Staruch, I., Ciążyńska, M., Sobolewska-Sztychny, D., Narbutt, J., Skibińska, M., & Lesiak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083998 · Cited by 212
Collins, S. M., Kassam, Z., & Bercik, P. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.004 · Cited by 205
Obesity: Pathophysiology and Intervention
Zhang, Y., Liu, J., Yao, J., Ji, G., Qian, L., Wang, J., Zhang, G., Tian, J., Nie, Y., Zhang, Y., et al. (2014) · Nutrients · doi:10.3390/nu6115153 · Cited by 189
“The intestinal microbiotas metabolize ingested nutrients into energy-rich substrates for utilization by the host and commensal flora [203,204] and adapt metabolically based on nutrient availability.”
BackgroundAssociations between Gut Microbiota and Common Luminal Intestinal Parasites
Stensvold, C. R., & van der Giezen, M. (2018) · Trends in Parasitology · doi:10.1016/j.pt.2018.02.004 · Cited by 187
From Stool Transplants to Next-Generation Microbiota Therapeutics
Petrof, E. O., & Khoruts, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.004 · Cited by 186
Jolanta Wasilewska, J., & Klukowski, M. (2015) · Pediatric Health, Medicine and Therapeutics · doi:10.2147/phmt.s85717 · Cited by 182
“Today’s knowledge, however, allows for experimental therapeutic use of fecal microbiota transplantation (FMT) (approved by the US Food and Drug Administration in 2013) mainly as a treatment for patients suffering from Clostridium difficile infection (CDI).(114) Children diagnosed with ASD and CDI are considered as pot…”
BackgroundRapidly expanding knowledge on the role of the gut microbiome in health and disease
Cénit, M. C., Matzaraki, V., Tigchelaar, E. F., & Zhernakova, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.023 · Cited by 184
Dash, S., Syed, Y. A., & Khan, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.880544 · Cited by 171
“FMT has been reported to treat IBD and IBS successfully, resulting in a typical gut microbiota composition in patients, improving constipation symptoms (Aroniadis and Brandt, 2013; Rossen et al., 2015).”
BackgroundMicrobiomes: unifying animal and plant systems through the lens of community ecology theory
Christian, N., Whitaker, B. K., & Clay, K. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00869 · Cited by 166
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease
Guo, X., Huang, C., Xu, J., Xu, H., Liu, L., Zhao, H., Wang, J., Huang, W., Peng, W., Chen, Y., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.818902 · Cited by 165
“Remission rates were significantly higher in the FMT group than in the placebo group, with no difference in the incidence of adverse events.”
BackgroundInfluentialThe Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162
Green, J. E., Davis, J. A., Berk, M., Hair, C., Loughman, A., Castle, D., Athan, E., Nierenberg, A. A., Cryan, J. F., Jacka, F., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1854640 · Cited by 155
“For the purposes of this review, FMT was defined as any process by which a fecal microbiota suspension was transferred from the gastrointestinal tract of a healthy individual into another person with the aim of treating a health condition.(35) ● Comparator: Studies were included if they utilized a control group.”
MethodProbiotics for Parkinson’s Disease
Gazerani, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174121 · Cited by 151
“Non-GI diseases have also been investigated to find whether FMT can be beneficial, and this area includes CNS disorders [131] including autism and multiple sclerosis [132].”
BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview
Deumer, U.-S., Varesi, A., Floris, V., Savioli, G., Mantovani, E., López-Carrasco, P., Rosati, G. M., Prasad, S., & Ricevuti, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204786 · Cited by 181
Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders
Evrensel, A., & Ceylan, M. E. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.3.231 · Cited by 150
Correlation between human gut microbiome and diseases
Madhogaria, B., Bhowmik, P., & Kundu, A. (2022) · Infectious Medicine · doi:10.1016/j.imj.2022.08.004 · Cited by 198
“Case reports and animal models demonstrated the effectiveness of FMT against an array of differ-ent disorders like metabolic disorders, insulin sensitivity, multiple sclerosis, autism etc. [ 69 , 70 ].”
BackgroundCastro‐Marrero, J., Sáez‐Francàs, N., Santillo, D., & Alegre, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13702 · Cited by 164
“symptoms over a period of 11–28 months (Aroniadis and Brandt, 2013).”
BackgroundGut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?
Cammarota, G., Ianiro, G., Bibbò, S., & Gasbarrini, A. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1069-4 · Cited by 167
“6–8 h after the donation [78, 79].”
Sha, S., Liang, J., Chen, M., Xu, B., Liang, C., Wei, N., & Wu, K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12699 · Cited by 134
“Improvement in autistic symptoms was reported in two children after FMT and in five children who received daily cultured Bacteroidetes and Clostridia for several weeks.(52) Neurologic improvement has also been reported in one patient with Parkinson’s disease who received FMT for chronic constipation.”
Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome
Steinway, S. N., Biggs, M. B., Loughran, T. P., Papin, J. A., & Albert, R. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004338 · Cited by 130
“2 billion [11].”
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7186 · Cited by 119
García-Gutiérrez, E., Narbad, A., & Rodríguez, J. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.578666 · Cited by 134
Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review
Bafeta, A., Yavchitz, A., Riveros, C., Batista, R., & Ravaud, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2810 · Cited by 111
“F microbiota transplantation (FMT) is an intervention whereby healthy donor stool is transplanted into a patient to restore the gut microbiome (1).”
BackgroundHealthy hosts rule within: ecological forces shaping the gut microbiota
Byndloss, M. X., Pernitzsch, S. R., & Bäumler, A. J. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0010-y · Cited by 109
Shankar, V., Hamilton, M. J., Khoruts, A., Kilburn, A., Unno, T., Paliy, O., & Sadowsky, M. J. (2014) · Microbiome · doi:10.1186/2049-2618-2-13 · Cited by 106
“factor, are possible candidates to which FMT could be applied with success [47,48].”
Samsam, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9942 · Cited by 106
LeBlanc, A. D. M. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16518 · Cited by 101
The Human Gut Microbiome as a Potential Factor in Autism Spectrum Disorder
Alharthi, A., Alhazmi, S., Alburae, N., & Bahieldin, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031363 · Cited by 98
Microbial community design: methods, applications, and opportunities
Eng, A., & Borenstein, E. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.03.002 · Cited by 113
Vrieze, A., de Groot, P. F., Kootte, R. S., Knaapen, M., van Nood, E., & Nieuwdorp, M. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.03.003 · Cited by 118
“Although intestinal microbe infusions used in veterinary practice in the Western world can be dated back to the 17th century as a treatment for ruminal acidosis (4), application in humans took until 1958, when Eiseman described the first”
BackgroundEltokhi, A., Janmaat, I. E., Genedi, M., Haarman, B. C. M., & Sommer, I. E. C. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24616 · Cited by 98
“FMT is commonly used in the treatment of GI diseases such as Clostridium difficile infection, Crohn's disease, and ulcerative colitis (Anderson, Edney, & Whelan, 2012; Aroniadis & Brandt, 2013; Xu et al., 2015).”
MethodMazzawi, T., Lied, G. A., Sangnes, D. A., El-Salhy, M., Hov, J. R., Gilja, O. H., Hatlebakk, J. G., & Hausken, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194904 · Cited by 92
Wei, Y., Zhu, W., Gong, J., Guo, D., Gu, L., Li, N., & Li, J. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/517597 · Cited by 91
“A hypothesis suggests that IBD results from continuous antigenic stimulation by nonpathogenic commensals, leading to an exaggerated sustained immune response in genetically predisposed hosts [12].”
BackgroundIntestinal microbiota could transfer host Gut characteristics from pigs to mice
Diao, H., Yan, H., Xiao, Y., Yu, B., Yu, J., He, J., Zheng, P., Zeng, B., Wei, H., Mao, X., et al. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0851-z · Cited by 104
An ecological framework to understand the efficacy of fecal microbiota transplantation
Xiao, Y., Angulo, M. T., Lao, S., Weiss, S. T., & Liu, Y.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17180-x · Cited by 89
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Gut microbiota regulates key modulators of social behavior
Parashar, A., & Udayabanu, M. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.11.002 · Cited by 88
“Clinically, several case reports suggest the beneficial role of fecal Transplant in treating gastrointestinal and nongastrointestinal symptoms in patients with neurologic disorders (Aroniadis and Brandt, 2013).”
BackgroundHarnessing the Microbiome to Prevent Fungal Infections: Lessons from Amphibians
Walke, J. B., & Belden, L. K. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005796 · Cited by 98
“Furthermore, microbiome engineering [35] to generate a protective microbiome structure and/or function may be a useful strategy, as the use of complete microbiome transplants in humans can effectively limit disease [36].”
BackgroundKelly, C. R., Kunde, S. S., & Khoruts, A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.060 · Cited by 79
Jayasinghe, T. N., Chiavaroli, V., Holland, D. J., Cutfield, W. S., & O'Sullivan, J. M. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00015 · Cited by 77
Dorożyńska, I., Majewska‐Szczepanik, M., Marcińska, K., & Szczepanik, M. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2013.09.007 · Cited by 79
“A growing evidence shows that there is a correlation between microbial dysbiosis and human pathology which includes autoimmunity, allergic diseases, obesity, inflammatory bowel disease (IBD), metabolic syndrome and even autism [3,6,13,19,26].”
BackgroundSbahi, H., & Di Palma, J. A. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000087 · Cited by 75
“of recurrent Clostridium difficile infection (RCDI).(6) 7 All delivery methods seem to be”
BackgroundInferring human microbial dynamics from temporal metagenomics data: Pitfalls and lessons
Cao, H., Gibson, T. E., Bashan, A., & Liu, Y. (2017) · BioEssays · doi:10.1002/bies.201600188 · Cited by 75
“For each initial condition change (which mimics the immediate result of an FMT), the system will respond by displaying certain transient behavior before it reaches the equilibrium (steady) state.”
BackgroundInfluentialApproaches to studying and manipulating the enteric microbiome to improve autism symptoms
Frye, R. E., Slattery, J., MacFabe, D. F., Allen-Vercoe, E., Parker, W., Rodakis, J., Adams, J. B., Krajmalnik-Brown, R., Bolte, E., Kahler, S., et al. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.26878 · Cited by 73
“These disorders include GI diseases such as inflammatory bowel disease, irritable bowel syndrome, and chronic constipation as well as non-GI diseases such as autoimmune diseases, chronic fatigue syndrome, and obesity (40).”
BackgroundBella, S. D., Gouliouris, T., & Petrosillo, N. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.01.011 · Cited by 77
The Brain-Gut-Microbiome Axis: What Role Does it Play in Autism Spectrum Disorder?
Luna, R. A., Savidge, T. C., & Williams, K. C. (2016) · Current Developmental Disorders Reports · doi:10.1007/s40474-016-0077-7 · Cited by 73
“child should give clinicians and families pause before implementing these treatments in children with ASD [36, 37].”
BackgroundImplications of the human microbiome in inflammatory bowel diseases
Bakhtiar, S. M., LeBlanc, J. G., Salvucci, E., Ali, A., Martin, R., Langella, P., Chatel, J.-M., Miyoshi, A., Bermúdez-Humarán, L. G., & Azevedo, V. (2013) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12111 · Cited by 72
“…with resultant cure of recurrent Clostridium difficile infection (CDI), and has also been used to treat other gastrointestinal diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders (Aroniadis & Brandt, 2013).”
BackgroundStep-up fecal microbiota transplantation (FMT) strategy
Cui, B., Li, P., Xu, L., Peng, Z., Xiang, J., He, Z., Zhang, T., Ji, G., Nie, Y., Wu, K., et al. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1151608 · Cited by 71
Ganci, M., Suleyman, E., Butt, H., & Ball, M. (2019) · Brain and Behavior · doi:10.1002/brb3.1408 · Cited by 83
“…treating various conditions including but not limited to GI disorders (Brandt & Aroniadis, 2013), Parkinson's disease (Ananthaswamy, 2011), autism (Aroniadis & Brandt, 2013), and ME/CFS (Borody, Nowak, & Finlayson, 2012) is perhaps due to the proliferation of research associating microbial…”
BackgroundSong, X., Liu, Y., Zhang, X., Weng, P., Zhang, R., & Wu, Z. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.02.005 · Cited by 87
Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature
Cohen, N. A., & Maharshak, N. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4535-9 · Cited by 71
“An observational study involving autistic patients reported a remission of autistic symptoms in 2 patients post-FMT [77].”
Bonfrate, L., Tack, J., Grattagliano, I., Cuomo, R., & Portincasa, P. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.799220 · Cited by 67
“FMT has been used during the time also to cure other GI diseases, including IBD, IBS and chronic functional constipation as well as non-GI diseases, including Parkinson’s disease, chronic fatigue and autism [142].”
BackgroundVemuri, R. C., Gundamaraju, R., Shinde, T., & Eri, R. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0115 · Cited by 66
Sensitivity to oxazolone induced dermatitis is transferable with gut microbiota in mice
Zachariassen, L. F., Krych, L., Engkilde, K., Nielsen, D. S., Kot, W., Hansen, C. H. F., & Hansen, A. K. (2017) · Scientific Reports · doi:10.1038/srep44385 · Cited by 66
Clinical Evidence for the Microbiome in Inflammatory Diseases
Slingerland, A. E., Schwabkey, Z. I., Wiesnoski, D. H., & Jenq, R. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00400 · Cited by 70
“Newer treatment modalities include fecal microbiota transplant (FMT), introducing the complete microbial ecology of a healthy donor to restore phylogenetic diversity and synergistic function (11), and administration of bacterial metabolic byproducts such as short-chain fatty acids or conjugated bile acids (12).”
BackgroundZhang, X., Tian, H., Gu, L., Nie, Y., Ding, C., Ge, X., Yang, B. K., Gong, J., & Li, N. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9229-1 · Cited by 68
“It has also been shown to be effective in treating inflammatory bowel disease, irritable bowel syndrome, and a variety of non-GI disorders (Aroniadis and Brandt, 2013).”
BackgroundVaresi, A., Deumer, U.-S., Ananth, S. V., & Ricevuti, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215077 · Cited by 73
“Moreover, several authors underline that no solid conclusions can be drawn from existing studies, and larger clinical trials are needed in order to clarify FMT efficiency in various human disorders [162,170,174,180,181].”
BackgroundAlteration of Gut Microbiota: New Strategy for Treating Autism Spectrum Disorder
Liu, J., Gao, Z., Chuanqi, L., Liu, T., Gao, J., Cai, Y., & Fan, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.792490 · Cited by 86
Chemoprevention in Gastrointestinal Physiology and Disease. Natural products and microbiome
Greiner, A. K., Papineni, R. V. L., & Umar, S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00044.2014 · Cited by 62
“In addition to colonic disease, FMT may also prove useful to treat various other conditions, including colitis, constipation, IBS, and some neuropsychiatric conditions (6).”
BackgroundEquine faecal microbiota transplant: Current knowledge, proposed guidelines and future directions
Mullen, K. R., Yasuda, K., Divers, T. J., & Weese, J. S. (2016) · Equine Veterinary Education · doi:10.1111/eve.12559 · Cited by 72
“The potential mechanisms by which FMT improves outcome in other GI and non-GI disorders are being actively investigated, as is the determination of the direction of causality and reversibility of these conditions (Aroniadis and Brandt 2013; Smits et al. 2013; Khoruts and Weingarden 2014).”
BackgroundMethodInfluentialKashtanova, D. A., Tkacheva, O. N., Strazhesko, I. D., Dudinskaya, Е. N., Kotovskaya, Y. V., Popenko, A., Tyakht, A., & Alexeev, D. G. (2019) · Healthy ageing and longevity · doi:10.1007/978-3-030-24970-0_17 · Cited by 59
Cristiano, C., Lama, A., Lembo, F., Mollica, M. P., Calignano, A., & Mattace Raso, G. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00184 · Cited by 58
“FMT in autistic children has been described by Aroniadis and Brandt (2013).”
BackgroundEndam, L. M., Alromaih, S., González, E., Madrenas, J., Cousineau, B., Renteria, A. E., & Desrosiers, M. Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00440 · Cited by 62
“Stool “transplants,” where healthy flora from normal donors are introduced into diseased colon, has been shown to control colonic inflammation of various etiologies (Snelling, 2005; Wolvers et al., 2010; Aroniadis and Brandt, 2013).”
BackgroundMiller, A. W., Dale, C., & Dearing, M. D. (2017) · mSystems · doi:10.1128/msystems.00088-17 · Cited by 63
Shang, L., Yu, H., Liu, H., Chen, M., Zeng, X., & Qiao, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111127 · Cited by 60
Development of Fecal Microbiota Transplantation Suitable for Mainstream Medicine
Khoruts, A., Sadowsky, M. J., & Hamilton, M. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.014 · Cited by 58
Metadata
- Authors
- Aroniadis, O. C., & Brandt, L. J.
- Affiliations
- Montefiore Medical Center (US)
- Corresponding author
- Aroniadis, Olga C.
- Venue
- Current Opinion in Gastroenterology
- Published
- 2013-01
- Volume
- 29
- Issue
- 1
- Pages
- 79-84
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2025589766
- Cited by
- 336
- References
- 51
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 9 · 2022: 33 · 2021: 25 · 2020: 36 · 2019: 27 · 2018: 27 · 2017: 22 · 2016: 29 · 2015: 27 · 2014: 38 · 2013: 29
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, gut microbiota, Clostridium difficile infection, inflammatory bowel disease, irritable bowel syndrome, chronic constipation, autoimmune disease, obesity, chronic fatigue syndrome, neuropsychiatric disorders, energy metabolism, cell-mediated immunity
- MeSH terms
- Autistic Disorder, Autoimmune Diseases, Constipation, Enterocolitis, Pseudomembranous, Feces, Humans, Nervous System Diseases, Obesity, Recurrence, Inflammatory Bowel Diseases, Fatigue Syndrome, Chronic, Clostridioides difficile, Irritable Bowel Syndrome, Donor Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.